Sotyktu (deucravacitinib) PDUFA Date (Bristol Myers Squibb)
FDA PDUFA decision date for Sotyktu (deucravacitinib) is March 6, 2026. Developed by Bristol Myers Squibb. Indication: Psoriatic arthritis (PsA). Current status: Approved.
Indication
Psoriatic arthritis (PsA)
Notes
Label expansion for already-approved Sotyktu (plaque psoriasis).
Regulatory details
- Company: Bristol Myers Squibb
- Therapeutic area: Immunology / Rheumatology
- Application type: sNDA
- Review type: Standard
- PDUFA date: 2026-03-06
- Outcome: Approved